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ABSTRACT 
Mutations in the V-ATPase B1 subunit gene ATP6V1B1 cause autosomal-recessive dRTA. 
We previously identified a single nucleotide polymorphism (SNP) in the human B1 subunit 
(c.481G>A; p.E161K) that displayed greatly diminished pump function in vitro. To 
investigate the impact of this SNP on urinary acidification, we conducted a genotype-
phenotype analysis of recurrent stone formers in the Dallas and Bern kidney stone registries. 
32 of 555 (5.8 %) of the patients examined were heterozygous for the p.E161K SNP, the 
remaining 523 patients (94.2 %) carried two wild-type alleles. Adjusted for sex, age, BMI and 
dietary acid and alkali intake, p.E161K SNP carriers had a tendency to higher urinary pH on a 
random diet (6.31 versus 6.09; p=0.089). Under an instructed low Ca and Na diet, urinary pH 
was higher in p.E161K SNP carriers (6.555 versus 6.005; p<0.005). Kidney stones of 
p.E161K carriers were more likely to contain CaP than stones of wild-type patients. In acute 
NH4Cl loading, p.E161K carriers displayed a higher trough urinary pH (5.34 vs 4.89; p=0.01) 
than wild-type patients. 14.58 % of wild-type patients and 52.38% of p.E161K carriers were 
unable to acidify their urine below 5.3 and thus can be considered to have incomplete dRTA. 
In summary, our data indicate that recurrent stone formers with the V-ATPase B1 subunit 
p.E161K SNP exhibit a urinary acidification deficit with an increased prevalence of CaP 
containing kidney stones. The burden of E161K heterozygosity may be a forme fruste of 
dRTA. 
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INTRODUCTION 
Urinary acidification is achieved by H
+
 secretion from α–intercalated cells in the collecting 
duct [1]. In these cells, H
+
 furnished by the cytosolic carbonic anhydrase is translocated 
against a concentration gradient by the ATP-driven V-ATPase into the urine. 
Contemporaneous with apical H
+
 secretion, carbonic anhydrase liberates HCO3
-
 ions which 
exit the α–intercalated cell basolaterally via the AE1 chloride-base exchanger to complete 
transepithelial acid-base transport. Dysfunction of α–intercalated cells causes dRTA, which is 
characterized by metabolic acidosis in the presence of unduly alkaline urine, growth 
retardation, rickets, nephrolithiasis, nephrocalcinosis, hypokalemia, and progressive renal 
failure [2]. dRTA can be acquired or inherited. Mutations in the a4 and B1 subunits of the V-
ATPase, the AE1 chloride-base exchanger and the carbonic anhydrase type II enzyme were 
thus far identified as causes of inherit d dRTA in humans [3-6]. Mutations in a4 and B1 
subunits cause early onset, autosomal-recessive disease whereas AE1 mutations cause 
autosomal-dominant, later onset disease. Partial impairment of distal tubular acidification is 
known as incomplete dRTA and has been associated with osteoporosis and nephrolithiasis [7-
9]. In contrast to dRTA which is characterized by overt metabolic acidosis, blood pH and 
HCO3
-
 are normal in incomplete dRTA but maximal urinary acidification is impaired when 
challenged [7, 10]. The etiology of incomplete dRTA is unknown, but may be in part due to 
allelic variants of genes involved in H
+
 secretion in α–intercalated cells. 
The V-ATPase consists of two multi-subunit complexes, the V1 (head) and V0 (membrane 
anchored) subunits [11]. The 640 kDa V1 subunit is composed of subunits A, B, C, D, E, F, G 
and H. Mammals have two B subunits, the ubiquitous B2 isoform and the B1 isoform which 
is restricted to specialized epithelia of the inner ear, epididymis and intercalated cells [12]. 
Numerous homozygous and compound heterozygous missense, nonsense, frameshift and 
splice-site mutations along the B1 subunit gene ATP6V1B1 have been reported in individuals 
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with congenital dRTA [3, 13].  
We previously investigated disease-causing missense B1 subunit mutations in vitro [14]. In B 
subunit-defective yeast, wild-type human B1 but not mutant B1 subunits rescued the growth 
phenotype by functional complementation. With one exception (p.G316E mutation), all 
mutant B1 subunits studied caused disrupted V-ATPase assembly in cell-based and 
biochemical assays; i.e. the failure to assembly in mammalian cells and inability to 
complement in yeast were concordant features. The extension of our analysis to common 
ATP6V1B1 SNPs unexpectedly revealed that the SNP (c.481G>A; p.E161K) exhibits greatly 
diminished pump function in vitro with the yeast growth assay despite intact assembly in 
mammalian cells [14]. This lack of concordance between pump assembly and function is 
unique and raises the question of the whether this is truly a functional variant or some 
phenomenon specific to yeast hosts. If this variant allele affects urinary acidification in vivo is 
currently unknown. To address this question we conducted a genotype-phenotype analysis in 
recurrent stone formers (SF). 
 
RESULTS 
Screening and identification of p.E161K carriers 
To identify p.E161K carriers, we conducted a search in the kidney stone registries at the 
Charles and Jane Pak Center of Mineral Metabolism and Clinical Research, UT Southwestern 
Medical Center, Dallas, TX and at the Division of Nephrology, Hypertension and Clinical 
Pharmacology, University Hospital of Bern, Switzerland. The kidney stone registry in Bern 
was initiated in 2004 with the Dallas registry as a template. Thus, both stone registries contain 
patients that underwent the same detailed metabolic work-up protocols, including a one week 
controlled Ca (15-20 mmoles/day) and Na (100 mEqs/day) diet intervention protocol (for 
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details see Concise Methods). Patients in the Bern registry also underwent dual-energy X-ray 
absorptiometry (DEXA) analysis of bone mineral density (BMD). 555 patients in both 
registries met the inclusion criteria (age ≥ 18 years, written informed consent, at least one 
episode of kidney stone disease) and had no exclusion criterion (known medications and 
disease states interfering with urinary acidification, for details see Concise Methods). All 555 
patients were genotyped for the c.481G>A; p.E161K SNP using bidirectional Sanger 
sequencing of exon 6 of ATP6V1B1. To exclude additional mutations that could confound the 
analysis, we sequenced the coding regions and intro-exon boundaries of the two genes 
associated with autosomal-recessive dRTA in humans (ATP6V1B1 and ATPV0A4) in all 
p.E161K heterozygous SF included in the study. To distinguish benign from likely disease-
causing variants, we evaluated each variant individually on the basis of strict criteria as 
described in Concise Methods. The sequencing of the ATP6V1B1 and ATPV0A4 genes 
revealed no additional mutations and no additional, likely disease-causing variants. 
 
Baseline characteristics of study population 
Characteristics of the patients included in the analysis are depicted in Table 1. 32 of the 555 
recurrent SF included in the analysis were heterozygous (5.8 %) for the p.E161K SNP. None 
of the 555 recurrent SF analyzed were homozygous for the SNP. The frequency of p.E161K 
heterozygosity was similar in both registries (5.5 % in the Dallas registry, 5.9 % in the Bern 
registry). As expected for recurrent SF, there were twice as many males than females overall 
in the two cohorts. There were no significant sex differences between wild-type and 
heterozygous patients (74.2 % males versus 68.8% males respectively; p=0.50). However, 
heterozygous SF were younger at first presentation at the stone clinic (median 38.3 yr versus 
42.7 yr; p=0.042), had a lower BMI (median 25.0 kg/m
2 
versus 26.5 kg/m
2
; p=0.016) and 
were more likely to have a positive family history of kidney stone disease (60.7% versus 
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41.3%, p=0.044). Furthermore, calculi of p.E161K carriers were significantly more likely to 
contain CaP (70.0% versus 38.6%; p=0.005). 
DEXA analysis revealed no relevant differences in BMD between the two groups of patients. 
The prevalence of osteoporosis and osteopenia was equal in both groups. 
 
Blood and urinary biochemistries on random outpatient diet 
Blood and urinary biochemistries of patients on a random outpatient diet are depicted in Table 
2. There were no differences in plasma electrolytes or renal function between the two groups. 
Random blood glucose was higher in wild-type patients (median 5.0 mmol/l versus 4.8 
mmol/l; p=0.0159) and plasma bicarbonate was lower in heterozygous patients (mean 25.2 
mmol/l versus 26.1 mmol/l; p=0.0178). Heterozygous SF displayed non-significant trends to 
higher urinary pH (mean 6.31 versus 6.09; p=0.089) and a lower 24 hr citrate excretion 
(median 2.01 versus 2.79 mmol/24 hr; p=0.08). Normalization to K, K minus P and net 
gastrointestinal absorption (NGIA), all as surrogates of alkali intake, also showed numerically 
lower citrate values in heterozygotes that did not reach statistical significance. 24 hr sulfate 
excretion as a measure of animal protein intake, 24 hr ur nary ammonium (NH4), net acid 
excretion (NAE) and NGIA were comparable between the two groups of patients.  
 
Blood and urinary biochemistry on an outpatient diet low in Na and Ca 
Blood and urinary biochemistries on an instructed outpatient diet low in Na and Ca are 
depicted in Table 3. This diet is not meant as therapy but rather to control extrinsic dietary 
factors allowing one to observe the endogenous characteristics of the subjects [15]. Compared 
to the random outpatient diet, there were clear reductions in both groups of patients in 24 hr 
urinary Na and Ca excretion on the low Ca and Na diet, indicating adherence to the dietary 
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instructions. With the exception of plasma P which was higher in the heterozygous patients 
(mean 1.01 versus 0.92 mmol/l; p=0.042), blood chemistries revealed no relevant differences 
between the two groups. Heterozygous patients exhibited a significantly higher 24 hr urine pH 
(median 6.555 versus 6.005; p=0.0065), however there was no difference in 24 hr citrate 
excretion when diet was controlled (median 2.372 versus 2.653 mmol/24 hr; p=0.32). As was 
the case under random diet, 24 hr sulfate excretion, 24 hr urinary NH4, NAE and NGIA were 
comparable between the two groups under the low Na and Ca diet. 
 
Multivariate analyses 
In the unadjusted analysis, heterozygous carriers of the p.E161K SNP exhibit signs of 
impaired urinary acidification. This includes increased CaP content of calculi, lower plasma 
bicarbonate on a random outpatient diet and a lower urinary pH on a more controlled diet. We 
next performed a multivariate analysis to adjust for known predictors of acid-base 
homeostasis, including sex, age, BMI and dietary acid and alkali intake taking, taking 
between-center variability into account [16-18]. As shown in Table 4, after this adjustment, 
urinary pH on low Ca and Na diet remained significantly different between the two groups of 
patients. However, plasma bicarbonate under random outpatient diet was no longer different 
between the two groups. Due to the relatively low number of heterozygotes, logistic 
regression for stone analysis could not be performed with inclusion of all covariates. Table 5 
shows associations between p.E161 carriers and kidney stone type as odds ratios based on 
mixed effects logistic regression models, alternatively adjusting for sex, age and BMI or for 
combinations of two of these variables, taking center variability into account. E161K 
heterozygosity remains significantly associated with an increased CaP content of calculi. 
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Response to acute acid loading 
We next challenged the renal acid excretory capacity in wild-type (n=48) and heterozygous 
(n=21) SF by performing the standard NH4Cl loading test [7]. There were no significant age 
and sex differences between the two groups (Table 6). Urinary pH was measured at baseline 
and hourly for 6 consecutive hours after ingestion of NH4Cl gelatin capsules (0.1 g / kg body 
weight). As shown in Fig. 1A, there was no difference in the median fasting urinary pH at the 
beginning of the test (5.78 in wild-type versus 5.87 in heterozygous patients; p=0.71). 
However, we observed a clear difference in the trough urinary pH reached between the two 
groups of patients (median 4.89 in wild-type versus 5.34 in heterozygous patients; p=0.01; 
Mann-Whitney U test) (Fig. 1B). This significant difference in trough urinary pH persisted 
even after adjustment for sex and age (Fig. 1C). 7 of 48 wild-type (14.58%) and 11 of 21 
heterozygous patients (52.38%) were unable to acidify their urine below 5.3 and thus had 
incomplete dRTA (p=0.001, Chi-square test). Baseline and peak urinary NH4 concentration 
and urinary NH4 excretion profiles (AUC) were not different between the two groups of 
patients (Fig. 1D-F). 
 
Blood and urinary biochemistry in non SF with the p.E161K SNP 
To assess the impact of the p.E161K SNP on urinary pH in non SF, we performed an analysis 
of blood and urinary parameters of wild-type and p.E161K heterozygous non SF. Biochemical 
data and DNA of these individuals are deposited in the Dallas stone registry as non SF 
controls. Inclusion and exclusion criteria for non SF were identical to the ones used for SF 
with the exception that history of renal stone disease was an exclusion criterion. We identified 
a total of 148 wild-type and 14 p.E161K heterozygous non SF in the database that met the 
inclusion criteria and no exclusion criterion. There was no difference between the two groups 
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with regards to median age (39.9 years versus 35.7 years; p=0.37) or sex (40.5% men versus 
28.6% men; p=0.64). Blood and 24 hr urinary biochemistries of non SF on a random 
outpatient diet are depicted in Table 7. There were no differences in plasma electrolytes or 
renal function between the two groups. Median plasma bicarbonate tended to be lower in 
heterozygous than in wild-type non SF (24 mmol/l versus 27 mmol/l), but the difference did 
not reach statistical significance (p=0.15). Median urinary pH in heterozygous non SF was not 
different from wild-type non SF on a random outpatient diet (6.2 versus 6.1; p=0.44). 
However, similar to the observation made in SF, heterozygous non SF displayed a 
significantly higher 24 hr urine pH than wild-type non SF (median 6.7 versus 6.2; p=0.048 ) 
on an instructed diet (Table 8). This difference in 24 hr urine pH persisted even after 
adjustment for sex and age (p=0.05). 
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DISCUSSION 
Classically, congenital dRTA has been considered an autosomal-recessive disease. A recent 
study demonstrated that heterozygous carriers in a large family with a B1 truncation mutation 
(p.Phe468fsX487) were not normal but exhibited features of urinary acidification deficit and 
elevated stone risk [19]. The phenotype in heterozygotes of this peculiar mutation was 
attributed to haploinsufficiency since in vitro studies were not compatible with negative 
dominance of this mutation. The authors also failed to find evidence of negative dominance in 
vitro of other known B1 missense mutations and two common SNPs, including p.E161K. If 
the other known B1 subunit missense mutations also cause a detectable deficit in urinary 
acidification in a heterozygous state is currently unknown. The functional role of the B1 
subunit p.E161K SNP has not been studied in vivo.  
The goal of the current study was to investigate the phenotype of recurrent SF with the B1 
subunit p.E161K SNP. To our knowledge, this is the first study with a comprehensive 
analysis of the effect of a V-ATPase B1 SNP on urinary acidification. By combining patient 
data of the Dallas and Bern stone registries, we identified 32 heterozygous p.E161K carriers 
in a total of 555 recurrent SF, corresponding to an allele frequency of 5.8 %. This is slightly 
lower compared to a previous study that found the c.481G>A; p.E161K SNP to be in Hardy-
Weinberg equilibrium with an allele frequency of 10% [13]. We identified no homozygous 
patients in our cohort of 555 recurrent SF. Assuming Hardy-Weinberg equilibrium, the 
observed frequency of heterozygous patients in our cohort would correspond to a 
homozygosity frequency of 0.000883 %. Thus, ~1100 recurrent SF would be needed for the 
identification of one homozygous p.E161K carrier. 
Hildebrandt and colleagues recently studied a cohort of recurrent SF by high throughput 
mutation analysis of 30 genes known to cause kidney stone disease [20]. They detected in 
14.9 % of cases likely causative mutations in 14 of the 30 genes analyzed, indicating that 
monogenetic causes of recurrent nephrolithiasis are more prevalent than currently appreciated. 
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Interestingly, one patient in that analysis with recurrent nephrolithiasis, hypercalciuria and 
diminished plasma bicarbonate was found to be homozygous for the p.E161K SNP.  
Our analysis indicates that heterozygous p.E161K SF also exhibit subtle defects in urinary 
acidification. p.E161K heterozygous SF had a higher 24h urinary pH under a diet low in Ca 
and Na and a tendency to higher urinary 24 h urinary pH under random outpatient diet than 
wild-type SF. In support of these findings, p.E161K heterozygous non SF also exhibited a 
higher urinary pH under a diet low in Ca and Na than wild-type non SF. 
Challenging renal acid excretory capacity by acute acid loading unmasked the suspected 
acidification deficit in p.E161K heterozygous SF and unveiled a high prevalence of 
incomplete dRTA in this group of patients. Compatible with the findings of an increased 
urinary pH, the CaP content of calcareous stones was significantly higher in p.E161K SNP 
carriers. An alkaline urine favors CaP stone formation but decreases the risk of uric acid 
precipitation. Using computer-based methods (EQUIL2 [21] and JESS [22]) as well as 
empirical physicochemical methods, Pak and coworkers showed that raising urinary pH from 
6.0 to 6.5, such as we have observed in our two groups, will increase the brushite relative 
supersaturation ratio, saturation index and concentration product ratio from 2.1 to 4.5, 1.8 to 
2.3, and 1.4 to 2.5 respectively, thereby escalating risk of calcium phosphate stones [23]. 
Thus, the p.E161K SNP may augment the individual risk for development of renal calculi. 
However, due to the opposing effect on CaP and uric acid stone risk, the prevalence of the 
p.E161K SNP in the general population may not greatly differ from the one observed in 
recurrent SF. Clearly, additional studies will be needed to answer this question. 
In addition to defects in urinary acidification, B1 subunit mutations are associated with 
sensorineural hearing loss [3, 13]. In this study, we did not detect obvious hearing 
abnormalities in recurrent SF with the p.E161K carriers, but audiometric investigations were 
not performed and thus the impact of the p.E161K SNP on inner ear function remains 
unknown at the moment. 
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Patients with overt dRTA exhibit low BMD mainly due to low bone formation [24]. The case 
may be different in patients with a mild impairment in urinary acidification and normal 
systemic acid-base balance. A recent study detected no difference in BMD in recurrent SF 
with incomplete dRTA when compared with SF without RTA [25]. We also did not observe 
differences in BMD between p.E161K heterozygous and wild-type SF. This may be related to 
the fact that these subjects do not have sustained systemic acidosis to alter bone biology. 
In summary, our data indicate that recurrent SF with the V-ATPase B1 subunit p.E161K SNP 
exhibit a urinary acidification deficit with an increased prevalence of CaP containing kidney 
stones. The burden of E161K heterozygosity may be a forme fruste of distal RTA.  
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CONCISE METHODS 
 
Patients and study protocol 
The study was conducted with patients recruited at the Division of Nephrology, Hypertension 
and Clinical Pharmacology at the University Hospital of Bern, Switzerland and at the General 
Clinical Research Center at the University of Texas Southwestern Medical Center, Dallas, TX 
with approval by the Institutional Review Board (Dallas) or by the Ethical Committee of the 
Kanton Bern (Bern). All participants provided written informed consent and the study was 
conducted in accordance with the Declaration of Helsinki. Patients in the registries were seen 
at the clinic between March 2004 and March 2014, suffered from at least one stone episode 
and underwent a three visit mineral metabolism work-up. Mineral metabolism work up 
included a 24 hr urine on a random outpatient diet and one 24 hr urine after one week under 
an instructed low Ca (15-20 mmoles/day) and Na (100 mEqs/day) diet according to a protocol 
first established by Pak et al. [26, 27]. Urine and blood analysis were performed at the Central 
Laboratory of the University Hospital of Bern, Switzerland or at the Center of Mineral 
Metabolism and Clinical Research University of Texas Southwestern Medical Center, Dallas, 
TX using standard laboratory methods. Blood gas analysis was done on venous blood 
samples. Estimated GFR was calculated according to CKD-EPI [28]. Osteodensitometry was 
performed at the Department of Osteoporosis at the University Hospital of Bern, Switzerland 
by dual-energy X-ray absorptiometry (DEXA; Hologic QDR 4500A, Hologic, Bedford, MA, 
USA) at the lumbar spine, the non-dominant femoral neck, the proximal femur, the distal 
tibial diaphysis and epiphysis. Charts of all patients in the registry were reviewed manually 
for this study. Inclusion criteria were: informed consent and at least one stone episode. 
Exclusion criteria for analysis were: Absence of informed consent, genetic diseases causing 
distal renal tubular acidosis, cystinuria, primary hyperoxaluria, primary or secondary 
hyperparathyroidism, autoimmune diseases, renal diseases, malignancy, hypo- or 
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hyperthyroidism, liver diseases, short bowel syndrome or bariatric surgery, chronic urinary 
tract infection, pregnancy, mineralocorticoid deficiency, anorexia nervosa, metabolic acidosis, 
diarrhoea or medications interfering with urinary acidification during the investigation. 
Biochemical data and DNA of non-stone forming individuals used in the study are deposited 
in the Dallas stone registry as non SF controls. Inclusion and exclusion criteria for non SF 
included in this study were identical to the ones used for SF with the exception that history of 
renal stone disease was an exclusion criterion. 
 
DNA extraction and genotpying 
Genomic DNA was extracted from peripheral blood leucocytes using a Nucleospin
®
 Blood L 
(Macherey-Nagel, Switzerland) DNA extraction kit. In all subjects included in the study (SF 
and non SF), exon 6 with adjacent exon-intron boundaries of the ATP6V1B1 gene was 
individually amplified by PCR (AmpliTaq Gold system, Applied Biosystems) using primers 
described previously [3]. The DNA sequence of both strands was determined by Sanger 
sequencing at Microsynth AG, Switzerland. In addition, in all of the 32 p.E161K 
heterozygous SF, coding sequences and intron-exon boundaries of ATP6V0A4 and ATP6V1B1 
were sequenced using TruSeq Custom Amplicon v1.5 (Illumina) on a MiSeq (Illumina). Data 
were analysed using integrated MiSeq Reporter v2.5.1. Mutations were considered to be 
known if they were deposited in the Human Gene Mutation Database 
(http://www.hgmd.cf.ac.uk/ac/index.php). Nonsynonymous variants were considered as likely 
disease-causing according to the following inclusion and exclusion criteria [29]: Inclusion 
criteria  (1) truncating mutation (stop gained, abrogation of start or stop codon, abrogation of 
obligatory splice site, or frame shift) or (2) missense mutation if one of the following is 
applied: (1) in silico prediction by Polyphen2-HumVar with a score > 0.90, suggesting a 
probably damaging effect on the protein level [30] or (2) the given disease-causing allele is 
Page 15 of 33
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 15 of 31 
 
supported by functional data. Exclusion criteria: (1) allele is present in healthy controls of the 
Exome Variant Server database with a minor allele frequency of > 5.0%. 
 
Acute acid loading 
All p.E161K carriers were invited to participate in the acute acid loading test. Recruitment of 
wild-type SF for NH4Cl loading was as follows: all patients referred to our stone clinic for 
metabolic work up of stone disease that met the inclusion criteria but no exclusion criterion 
(see section “Patients and Study protocol”) were consecutively enrolled, irrespective of 
baseline urinary pH, sex or age. Genotyping was performed after acid loading. Acid loading 
was performed using the short NH4Cl loading test as described [7, 31]. NH4Cl gelatin 
capsules (0.1 g / kg body weight) were given to fasting subjects at 0800 hrs with water in the 
presence of the nursing staff. During the test, fluid intake was ad libitum. Venous blood 
samples were obtained for chemistry, pH and blood gases at 0800, 1000, 1200 hrs. Urine was 
collected hourly from 0800 to 1400 hrs. Urine pH was measured immediately after collection 
with an electrode pH meter that was calibrated every day. Urinary ammonium was assessed 
enzymatically by the glutamate dehydrogenase method. 
 
Statistical analysis 
Continuous variables with normal distribution are expressed as the mean±SD and in case of 
skewed distribution as the median (25
th
-75
th
 percentile). Categorical variables are expressed 
as numbers and frequencies in %. The shape of the distribution of each continuous variable 
was visually inspected and square root, log or inverse transformations were applied to ensure 
normality for statistical analyses. For a few number of variables no appropriate transformation 
was found. Welch’s t-test, Mann–Whitney U or chi-square tests were performed where 
appropriate to compare baseline characteristics for continuous and categorical variables. The 
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statistical tests were two-sided and a p-value < 0.05 was considered to indicate a statistically 
significant difference. 
In order to estimate the associations between the p.E161K SNP and acid-base parameters or 
kidney stone type, we first applied univariable linear or logistic regression analyses taking the 
between-center variability into account where available. We next analyzed the independent 
associations of the p.E161K SNP with the response variables and assumed that sex, age, BMI, 
dietary acid and alkali intake are most likely to influence these parameters and selected them 
as explanatory co-variables. We therefore performed a multivariate analysis of the influence 
of the p.E161K SNP adjusted for the main effects sex, age, BMI, urinary sulfate excretion and 
net gastrointestinal alkali absorption using linear regression and mixed effects linear and 
logistic regression models. We considered the presence of non-linear effects and of 
interactions and therefore included quadratic terms and interactions involving up to three 
different factors into the full model. Age and urinary sulfate excretion were square root 
transformed and BMI was transformed as its negative inverse. All continuous explanatory 
variables were centered to zero to address the potential problem of co-linearity that may be 
induced by adding squared terms and interaction terms to the models. No important co-
linearities between the prediction variables were detected upon inspection of scatterplot and 
correlation matrices and variance inflation factors. Backward selection was carried out to 
eliminate interaction terms and quadratic terms with a p-value of 0.10 or higher. All parent 
terms of significant higher order terms were kept in the model. All main effects were also kept 
in the model irrespective of their significance. Due to the small number of heterozygotes the 
mixed effects logistic regression models did not converge when applying the full model. 
Therefore, for binary outcomes of kidney stone parameters, mixed effects logistic regression 
models were run with the p.E161K SNP as the only fixed covariate, while adjusting for at 
most two alternating additional covariates at a time and taking the between-center variability 
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into account. Estimates for logistic regression with more than three fixed effects and with one 
random effect were not available because of a noninvertible singular Hessian (the matrix of 
second derivatives). Models were validated graphically if appropriate for 1.) homogeneity by 
plotting residuals versus fitted values, for 2.) normality by a histogram of the residuals and a 
quantile-quantile (QQ-) plot, for 3.) homoskedasticity by plotting residuals against each 
explanatory variable used in the final models. These visual inspections did not reveal any 
obvious deviations from homoskedasticity or normality.The statistical analysis was performed 
by using the R Statistics software version 3.0.2 [32]. 
  
Page 18 of 33
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 18 of 31 
 
ACKNOWLEDGMENTS 
DF was supported by the Swiss National Centres of Competence in Research (NCCRs) 
Kidney.CH and TransCure, the Swiss National Science Foundation (grants # 31003A_135503 
and # 31003A_152829) and by a Medical Research Position Award of the Foundation Prof. 
Dr. Max Cloëtta. OWM was supported by the National Institute of Health R01 DK091392-02, 
R01 DK081423-04, and R01 DK092461-02, the O’Brien Kidney Research Center (P30-DK-
07938), the Simmons Family Foundation, and the Charles and Jane Pak Foundation. We 
thank PD Dr. Christian Schindler, Senior statistician at the Swiss Tropical and Public Health 
Institute, Basel, Switzerland for expert statistical advice. Part of the results were presented at 
the 46th Annual Meeting of the Swiss Society of Nephrology 2014 held December 5, 2014, in 
Interlaken, Switzerland.  
  
Page 19 of 33
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 19 of 31 
 
DISCLOSURES 
DF has served on an advisory board for Otsuka Pharmaceuticals and received unrestricted 
research grants from Novartis and Abbvie. 
  
Page 20 of 33
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 20 of 31 
 
REFERENCES 
1. Wagner CA, Devuyst O, Bourgeois S, Mohebbi N: Regulated acid-base transport in 
the collecting duct. Pflugers Arch 458:137-156, 2009. 
2. Laing CM, Unwin RJ: Renal tubular acidosis. J Nephrol 19 Suppl 9:S46-52, 2006. 
3. Karet FE, Finberg KE, Nelson RD, Nayir A, Mocan H, Sanjad SA, Rodriguez-Soriano 
J, Santos F, Cremers CW, Di Pietro A, Hoffbrand BI, Winiarski J, Bakkaloglu A, 
Ozen S, Dusunsel R, Goodyer P, Hulton SA, Wu DK, Skvorak AB, Morton CC, 
Cunningham MJ, Jha V, Lifton RP: Mutations in the gene encoding B1 subunit of H+-
ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet 21:84-90, 
1999. 
4. Bruce LJ, Cope DL, Jones GK, Schofield AE, Burley M, Povey S, Unwin RJ, Wrong 
O, Tanner MJ: Familial distal renal tubular acidosis is associated with mutations in the 
red cell anion exchanger (Band 3, AE1) gene. J Clin Invest 100:1693-1707, 1997. 
5. Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE: Carbonic anhydrase II 
deficiency identified as the primary defect in the autosomal recessive syndrome of 
osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci 
U S A 80:2752-2756, 1983. 
6. Smith AN, Skaug J, Choate KA, Nayir A, Bakkaloglu A, Ozen S, Hulton SA, Sanjad 
SA, Al-Sabban EA, Lifton RP, Scherer SW, Karet FE: Mutations in ATP6N1B, 
encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal 
renal tubular acidosis with preserved hearing. Nat Genet 26:71-75, 2000. 
7. Wrong O, Davies HE: The excretion of acid in renal disease. Q J Med 28:259-313, 
1959. 
8. Backman U, Danielson BG, Sohtell M: Urine acidification capacity in renal stone 
formers. Scand J Urol Nephrol Suppl 35:49-61, 1976. 
9. Backman U, Danielson BG, Johansson G, Ljunghall S, Wikstrom B: Incidence and 
clinical importance of renal tubular defects in recurrent renal stone formers. Nephron 
25:96-101, 1980. 
10. Dedmon RE, Wrong O: The excretion of organic anion in renal tubular acidosis with 
particular reference to citrate. Clin Sci 22:19-32, 1962. 
11. Smith AN, Lovering RC, Futai M, Takeda J, Brown D, Karet FE: Revised 
nomenclature for mammalian vacuolar-type H+ -ATPase subunit genes. Mol Cell 
12:801-803, 2003. 
12. Miller RL, Zhang P, Smith M, Beaulieu V, Paunescu TG, Brown D, Breton S, Nelson 
RD: V-ATPase B1-subunit promoter drives expression of EGFP in intercalated cells 
of kidney, clear cells of epididymis and airway cells of lung in transgenic mice. Am J 
Physiol Cell Physiol 288:C1134-1144, 2005. 
13. Stover EH, Borthwick KJ, Bavalia C, Eady N, Fritz DM, Rungroj N, Giersch AB, 
Morton CC, Axon PR, Akil I, Al-Sabban EA, Baguley DM, Bianca S, Bakkaloglu A, 
Bircan Z, Chauveau D, Clermont MJ, Guala A, Hulton SA, Kroes H, Li Volti G, Mir 
S, Mocan H, Nayir A, Ozen S, Rodriguez Soriano J, Sanjad SA, Tasic V, Taylor CM, 
Topaloglu R, Smith AN, Karet FE: Novel ATP6V1B1 and ATP6V0A4 mutations in 
autosomal recessive distal renal tubular acidosis with new evidence for hearing loss. J 
Med Genet 39:796-803, 2002. 
14. Fuster DG, Zhang J, Xie XS, Moe OW: The vacuolar-ATPase B1 subunit in distal 
tubular acidosis: novel mutations and mechanisms for dysfunction. Kidney Int 
73:1151-1158, 2008. 
Page 21 of 33
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 21 of 31 
 
15. Pak CY, Odvina CV, Pearle MS, Sakhaee K, Peterson RD, Poindexter JR, Brinkley 
LJ: Effect of dietary modification on urinary stone risk factors. Kidney Int 68:2264-
2273, 2005. 
16. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY: Association of 
urinary pH with body weight in nephrolithiasis. Kidney Int 65:1422-1425, 2004. 
17. Maalouf NM, Cameron MA, Moe OW, Sakhaee K: Metabolic basis for low urine pH 
in type 2 diabetes. Clin J Am Soc Nephrol 5:1277-1281, 2010. 
18. Meschi T, Maggiore U, Fiaccadori E, Schianchi T, Bosi S, Adorni G, Ridolo E, 
Guerra A, Allegri F, Novarini A, Borghi L: The effect of fruits and vegetables on 
urinary stone risk factors. Kidney Int 66:2402-2410, 2004. 
19. Zhang J, Fuster DG, Cameron MA, Quinones H, Griffith C, Xie XS, Moe OW: 
Incomplete distal renal tubular acidosis from a heterozygous mutation of the V-
ATPase B1 subunit. Am J Physiol Renal Physiol 307:F1063-1071, 2014. 
20. Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, Fisher B, 
Spaneas L, Porath JD, Braun DA, Wassner AJ, Nelson CP, Tasic V, Sayer JA, 
Hildebrandt F: Fourteen Monogenic Genes Account for 15% of 
Nephrolithiasis/Nephrocalcinosis. J Am Soc Nephrol, 2014. 
21. Werness PG, Brown CM, Smith LH, Finlayson B: EQUIL2: a BASIC computer 
program for the calculation of urinary saturation. J Urol 134:1242-1244, 1985. 
22. Rodgers A, Allie-Hamdulay S, Jackson G: Therapeutic action of citrate in urolithiasis 
explained by chemical speciation: increase in pH is the determinant factor. Nephrol 
Dial Transplant 21:361-369, 2006. 
23. Pak CY, Moe OW, Maalouf NM, Zerwekh JE, Poindexter JR, Adams-Huet B: 
Comparison of semi-empirical and computer derived methods for estimating urinary 
saturation of brushite. J Urol 181:1423-1428, 2009. 
24. Domrongkitchaiporn S, Pongsakul C, Stitchantrakul W, Sirikulchayanonta V, 
Ongphiphadhanakul B, Radinahamed P, Karnsombut P, Kunkitti N, Ruang-raksa C, 
Rajatanavin R: Bone mineral density and histology in distal renal tubular acidosis. 
Kidney Int 59:1086-1093, 2001. 
25. Arampatzis S, Ropke-Rieben B, Lippuner K, Hess B: Prevalence and densitometric 
characteristics of incomplete distal renal tubular acidosis in men with recurrent 
calcium nephrolithiasis. Urol Res 40:53-59, 2012. 
26. Pak CY, Kaplan R, Bone H, Townsend J, Waters O: A simple test for the diagnosis of 
absorptive, resorptive and renal hypercalciurias. N Engl J Med 292:497-500, 1975. 
27. Pak CY, Britton F, Peterson R, Ward D, Northcutt C, Breslau NA, McGuire J, 
Sakhaee K, Bush S, Nicar M, Norman DA, Peters P: Ambulatory evaluation of 
nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am J Med 
69:19-30, 1980. 
28. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek 
JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to estimate 
glomerular filtration rate. Ann Intern Med 150:604-612, 2009. 
29. Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, Fisher B, 
Spaneas L, Porath JD, Braun DA, Wassner AJ, Nelson CP, Tasic V, Sayer JA, 
Hildebrandt F: Fourteen monogenic genes account for 15% of 
nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol 26:543-551, 2015. 
30. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, 
Kondrashov AS, Sunyaev SR: A method and server for predicting damaging missense 
mutations. Nat Methods 7:248-249, 2010. 
31. Karet FE, Gainza FJ, Gyory AZ, Unwin RJ, Wrong O, Tanner MJ, Nayir A, Alpay H, 
Santos F, Hulton SA, Bakkaloglu A, Ozen S, Cunningham MJ, di Pietro A, Walker 
WG, Lifton RP: Mutations in the chloride-bicarbonate exchanger gene AE1 cause 
Page 22 of 33
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 22 of 31 
 
autosomal dominant but not autosomal recessive distal renal tubular acidosis. Proc 
Natl Acad Sci U S A 95:6337-6342, 1998. 
32. Kimura S, Zhang GX, Nishiyama A, Shokoji T, Yao L, Fan YY, Rahman M, Abe Y: 
Mitochondria-derived reactive oxygen species and vascular MAP kinases: comparison 
of angiotensin II and diazoxide. Hypertension 45:438-444, 2005. 
 
  
Page 23 of 33
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 23 of 31 
 
FIGURE LEGENDS 
Figure 1. Acute acid loading by standard NH4Cl test in wild-type and p.E161K 
heterozygous SF.  
48 wild-type (WT) and 21 p.E161K heterozygous (E161K) SF underwent NH4Cl loading. 
68.8 % of WT and 71.4 % of E161K heterozygous SF tested were male (p=0.82). Median age 
of WT and E161K patients was 41.8 years (IQR 34.5-50.6) and 39.5 years (IQR 25.4-44.8), 
respectively (p=0.17).  
A) Urinary pH at beginning of the test before ingestion of NH4Cl capsules (time 0). B) 
Trough urinary pH (nadir pH) reached during the test. C) Trough urinary pH reached during 
the test, adjusted for sex and median age. For this conditional plot a linear regression model 
adjusted for sex and age was used. Age was set to the median of 41.8 years and sex to the 
most common category, men. D) Urinary NH4 at beginning of the test before ingestion of 
NH4Cl capsules (time 0). E) Peak urinary NH4 reached during the test. F) Urinary NH4 
excretion profile (area under the curve, AUC). Urinary NH4 levels were not available in all 
test participants. Between group differences are determined by Mann–Whitney U test or chi-
square test where appropriate and the corresponding p-value is indicated. 
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TABLES 
 
 
Table 1. Baseline patient characteristics according to E161K heterozygosity (N=555)  
Characteristic   Wild-type   Heterozygote   p 
Total stone patients   523 94.2% (of total)   32 5.8% (of total)     
    Center Bern   351 67.11%   22 68.75%   
0.85 
    Center Dallas   172 32.89%   10 31.25%   
Age at first presentation (yr)   514 42.65 (33.9-53.0)   31 38.30 (32.2-46.3)   0.042 
Male sex   382 74.2%   22 68.8%   0.50 
BMI (kg/m
2
)   479 26.5 (23.4-29.6)   29 25.0 (22.4-27.1)   0.015 
Positive family history of stones   179 41.3%   17 60.7%   0.044 
Patients with stones available for analysis   369 71.3%   20 62.5%   0.29 
Stones containing calcium oxalate   346 94.0%   18 90.0%   0.47 
Stones containing calcium phosphate   142 38.6%   14 70.0%   0.005 
Stones containing uric acid   19 5.2%   0 0%   0.30 
T-Score LWS    303  -0.51±1.05   20 -0.48±1.61   0.94 
T-Score Femur neck   300 -0.54±1.05   20 -0.57±0.97   0.92 
T-Score Tibia diaphysis   301 0.40±1.08   19 0.38±0.91   0.93 
T-Score Tibia epyphysis   300 -0.58±0.96   19 -0.65±0.87   0.74 
Osteoporosis present
a
   21 6.9%   1 4.8%   0.71 
Osteopenia present
a
   162 53.1%   13 61.9%   0.44 
The numer of stone formers is indicated for each characteristic stratified by the genotype. Categorical variables are 
further described by % and continuous variables by their mean ± standard deviation or by their median (25
th
-75
th
 
percentile). Between group differences are determined by Welch's t-test, Mann–Whitney U or chi-square test as 
appropriate and the corresponding p-value is indicated. 
a
Osteoporosis was defined as T-Score < -2.5 and Osteopenia as T-Score < -1.0 and > -2.5 
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Table 2. Blood and urine parameters according to E161K heterozygosity on random outpatient diet.  
Characteristic   
Normal 
range 
  Unit   N   Wild-type   N   Heterozygote   p 
Plasma Na   132 - 142   mmol/l   480   140.5±2.2   29   140.6±2.1   0.87 
Plasma K   3.5 - 4.7   mmol/l   480   3.9 (3.7-4.1)   29   4 (3.8-4.1)   0.28 
Plasma Cl   97 - 108   mmol/l   475   104 (102-106)   29   105 (102-107)   0.25 
Plasma Ca total   2.10 - 2.55   mmol/l   481   2.4 (2.3-2.4)   29   2.4 (2.3-2.5)   0.13 
Plasma Ca ionized   1.13 - 1.30   mmol/l   343   1.2 (1.2-1.2)   22   1.2 (1.2-1.2)   0.14 
Plasma P   0.84 - 1.45   mmol/l   481   1±0.2   29   1.1±0.2   0.11 
Plasma Mg   0.75 - 1.00   mmol/l   401   0.8 (0.8-0.9)   24   0.8 (0.8-0.9)   0.23 
Plasma Creatinine   59 - 104   µmol/l   481   80 (70-89)   29   80 (69-88)   0.52 
eGFR CKD-EPI   >90   ml/min/per 
1.73 m
2
 
  481   98.1 (83.8-109.9)   28   99 (87.5-114.1)   0.39 
Plasma urea   3.2 – 8.1   mmol/l   348   5.3 (4.5-6.3)   20   4.9 (4.3-5.6)   0.10 
Plasma uric acid   202 - 416   µmol/l   475   325±79.3   29   308.6±81.4   0.30 
Plasma random glucose   3.33 - 5.55   mmol/l   474   5.0 (4.6-5.6)   28   4.8 (4.4-5)   0.0159 
Blood pH   7.35 - 7.45   ─   344   7.392±0.029   22   7.398±0.032   0.38 
Plasma Bicarbonate   18.0 - 29.0   mmol/l   469   26.1±2.4   30   25.2±2   0.0178 
Plasma anion gap   8 - 16   mmol/l   317   10.3±2.5   21   9.8±2.2   0.31 
Serum PTH   15 - 65   pg/ml   427   38 (30-46)   26   34 (23.8-60.8)   0.74 
Serum 25-OH-Vitamin D   49 -134   nmol/l   222   40 (24.3-56)   10   35.5 (26.3-40.5)   0.29 
Serum 1,25-OH-Vitamin D   48 - 160   pmol/l   343   97 (72.5-125.5)   21   91 (70-132)   0.64 
Plasma  
Alkaline phosphatase 
  35 - 105   U/l   350   65 (55-76)   21   63 (57-74)   0.80 
Urine Dpd/creatinine   2.5 - 9.0   nmol/mmol   311   4 (3.4-4.9)   19   4.8 (3.8-5.5)   0.14 
Urine pyridinium crosslinks    ─   nmol/l   316   37.3 (23.4-56)   20   33 (19.8-49.1)   0.54 
Serum TSH   0.27-4.20   mU/l   347   1.3 (0.9-1.8)   22   1.3 (0.8-1.5)   0.55 
Urinary volume    ─   ml   502   1998 (1493-2618)   30   1887 (1609-2111)   0.67 
Urine pH    ─    ─   476   6.09±0.64   30   6.31±0.68   0.089 
Urine anion gap    ─   mmol/l   329   41.3±14.3   22   41.3±12.8   0.98 
Urine Na   40 - 220   mmol/24 hr   501   184 (141-236)   30   171.8 (130.1-230.6)   0.35 
Urine K   25 - 125   mmol/24 hr   501   60.5 (46-77)   30   58.3 (43.5-66.4)   0.077 
Urine Cl   110 - 250   mmol/24 hr   472   172.3 (128.4-225.5)   27   141 (117.5-209.7)   0.14 
Urine Ca   2.50 - 7.50   mmol/24 hr   500   6.26 (4.46-8.82)   30   6.82 (5.55-8.88)   0.52 
Urine P   13.0 - 42.0   mmol/24 hr   500   30.8 (24.1-38.9)   30   30.1 (26.1-36.1)   0.52 
Urine Mg   2.50 - 8.50   mmol/24 hr   497   4.34 (3.29-5.42)   30   4.35 (3.8-4.93)   0.59 
Urine uric acid   < 5900   µmol/24 hr   500   3500 (2935-4270)   30   3216 (2633-3594)   0.0039 
Urine urea   96 - 556   mmol/24 hr   349   410.6 (329.3-509.3)   22   364.4 (288.6-513.2)   0.21 
Urine creatinine   
8600 - 
19400 
  µmol/24hr   502   14334±4046   30   13519±3300   0.20 
Urine citrate   1.65 - 6.6   mmol/24 hr   487   2.79 (1.81-4.02)   28   2.01 (1.36-3.09)   0.080 
Urine citrate/K    ─   (mmol/24hr)/ 
(mmol/24hr) 
  487   0.046 (0.032-0.064)   28   0.041 (0.023-0.05)   0.12 
Urine K-P    ─   mmol/ 24 hr   500   28.4 (17.3-41.9)   30   22.6 (14.3-37.1)   0.083 
Urine citrate/K-P    ─   (mmol/24hr)/ 
(mmol/24hr) 
  485   0.098 (0.063-0.173)   28   0.094 (0.043-0.162)   0.41 
NGIA    ─   mmol/24 hr   468   30.76±29.67   27   26.51±28.62   0.46 
Urine SO4    ─   mmol/24 hr   487   22.2 (16.3-28.5)   28   20.4 (15.5-28)   0.74 
Urine oxalate   <500   µmol/24 hr   492   382.4 (286.1-559.4)   28   358 (268.8-482.8)   0.079 
Urine glycolate   150 - 600   µmol/24 hr   331   371.5 (148.5-574.9)   20   357.5 (182.4-499.3)   0.56 
Urine NH4   10 - 107   mmol/24 hr   96   36.8±15.9   4   31.9±4.7   0.32 
NAE    ─   mmol/24 hr   96   90.1 (63.3-103.8)   4   74.2 (67.32-80.9)   0.20 
Urine NH4/SO4    ─   (mmol/24hr)/ 
(mmol/24hr) 
  96   1.82 (1.41-2.18)   4   1.9 (1.77-2.9)   0.46 
Urine NH4/NAE    ─   (mmol/24hr)/ 
(mmol/24hr) 
  96   0.405±0.092   4   0.447±0.125   0.56 
The number of stone formers is indicated for each characteristic stratified by the genotype. Continuous variables are further described by 
their mean ± standard deviation or median (25
th
-75
th
 percentiles) as appropriate. Between group differences are determined by Welch's t-test 
or Mann–Whitney U test as appropriate and the corresponding p-value is indicated. Abbreviations: PTH, parathormone; TSH, thyroid 
stimulating hormone; NGIA, net gastrointestinal alkali intake; NH4, ammonium; SO4, sulfate; NAE, net acid excretion; p, p-value. 
Page 26 of 33
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 26 of 31 
 
 
 
 
 
 
Table 3. Blood and urine parameters according to E161K heterozygosity on a low Ca and Na diet. 
Characteristic   Normal range   Unit   N Wild-type   N Heterozygote   p 
Plasma Na   132 - 142   mmol/l   317 139.2±1.8   21 139.4±1   0.39 
Plasma K   3.5 - 4.7   mmol/l   317 3.813±0.262   21 3.848±0.186   0.43 
Plasma Cl   97 - 108   mmol/l   214 101.7±2.3   10 101.1±1.2   0.16 
Plasma Ca total   2.10 - 2.55   mmol/l   311 2.31 (2.25-2.39)   21 2.34 (2.3-2.44)   0.12 
Plasma Ca ionized   1.13 - 1.30   mmol/l   303 1.194±0.048   19 1.206±0.041   0.23 
Plasma P   0.84 - 1.45   mmol/l   316 0.92±0.174   21 1.012±0.191   0.042 
Plasma Mg   0.75 - 1.00   mmol/l   212 0.845 (0.8-0.89)   10 0.825 (0.775-0.848)   0.16 
Plasma Creatinine   59 - 104   µmol/l   312 81 (71-90)   21 77 (73-89)   0.93 
Plasma uric acid   202 - 416   µmol/l   287 363±89   19 337±63   0.10 
Blood pH   7.35 - 7.45    ─   292 7.387±0.029   19 7.391±0.042   0.68 
Plasma Bicarbonate   18.0 - 29.0   mmol/l   275 26±2.1   18 26.3±2.1   0.51 
Plasma anion gap   8 - 16   mmol/l   198 11.5±1.8   10 11.8±1.7   0.63 
Urinary volume    ─   ml   453 2200 (1620-2840)   30 1903 (1405-2558)   0.17 
Urine pH    ─    ─   392 6.005 (5.63-6.4)   24 6.555 (5.958-6.875)   0.0065 
Urine anion gap   ─   mmol/l   295 30 (22.2-39.2)   21 30.1 (24.4-47.6)   0.31 
Urine Na   40 - 220   mmol/ 24 hr   452 92.5 (62-129)   30 90 (47.5-118.5)   0.16 
Urine K   25 - 125   mmol/ 24 hr   450 54 (39-70.8)   30 43 (27.8-60.8)   0.15 
Urine Cl   110 - 250   mmol/ 24 hr   419 80 (55-119)   26 67 (41.8-101.3)   0.097 
Urine Ca   2.50 - 7.50   mmol/ 24 hr   452 4.04 (2.485-6.113)   30 3.56 (2.603-5.643)   0.79 
Urine P   13.0 - 42.0   mmol/ 24 hr   451 26.1 (19.9-32.5)   30 21 (18.2-28.6)   0.086 
Urine Mg   2.50 - 8.50   mmol/ 24 hr   445 3.87 (2.96-4.75)   30 3.32 (2.828-4.09)   0.14 
Urine uric acid   < 5900   µmol/ 24 hr   451 3403 (2641-4260)   29 3011 (2396-3886)   0.042 
Urine urea   96 - 556   mmol/ 24 hr   314 355.2 (266.8-445.8)   21 345.4 (192.1-418)   0.44 
Urine creatinine   8600 - 19400   µmol/ 24hr   451 14248 (10841-17092)   30 13678 (10208-16163)   0.29 
Urine citrate   1.65 - 6.6   mmol/ 24 hr   442 2.653 (1.668-3.784)   27 2.372 (1.623-3.299)   0.32 
Urine citrate/K    ─   (mmol/24hr)/ 
(mmol/24hr) 
  441 0.048 (0.034-0.068)   27 0.056 (0.033-0.071)   0.56 
Urine K-P    ─   mmol/ 24 hr   450 26.7 (13.1-44.2)   30 19.3 (5.3-38.9)   0.86 
Urine citrate/K-P    ─   (mmol/24hr)/ 
(mmol/24hr) 
  440 0.092 (0.057-0.153)   27 0.099 (0.043-0.135)   0.66 
NGIA    ─   mmol/ 24 hr   413 25.6 (10.1-40.9)   26 24.7 (6.4-45.5)   0.51 
Urine SO4    ─   mmol/ 24 hr   443 18.3 (13-23.3)   25 19.5 (11.5-21.3)   0.96 
Urine oxalate   <500   µmol/ 24 hr   448 418 (311-605)   26 395 (290-638)   1.00 
Urine glycolate   150 - 600   µmol/ 24 hr   310 320 (168-467)   18 329 (154-458)   0.83 
Urine NH4   10 - 107   mmol/ 24 hr   80 37.4 (28.8-47.5)   3 35.7 (27.5-48.7)   0.91 
NAE    ─   mmol/ 24 hr   80 85.9 (67.8-108.1)   3 70.4 (65.9-83.8)   0.37 
Urine NH4/SO4    ─   (mmol/24hr)/ 
(mmol/24hr) 
  80 1.895 (1.631-2.515)   3 2.38 (1.904-5.04)   0.50 
Urine NH4/NAE    ─   (mmol/24hr)/ 
(mmol/24hr) 
  80 0.438 (0.378-0.487)   3 0.507 (0.41-0.57)   0.71 
 
The number of stone formers is indicated for each characteristic stratified by the genotype. Continuous variables are further described by 
their mean ± standard deviation or median (25
th
-75
th
 percentiles) as appropriate. Between group differences are determined by Welch's t-
test or Mann–Whitney U test as appropriate and the corresponding p-value is indicated. Abbreviations: NGIA, net gastrointestinal alkali 
intake; NH4, ammonium; SO4, sulfate; NAE, net acid excretion; p, p-value. 
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Table 4: Associations between the E161K polymorphism and plasma and urinary acid-base parameters estimated by linear regression models and 
mixed effects linear regression models. 
 
E161K unadjusted   E161K adjusted 
Response variable β 95% CI p 
 
β 95% CI p 
Under random diet        
Plasma bicarbonate (mmol/l) (n=439) -0.6633 -1.629;0.302 0.18  -0.697 -1.608;0.2138 0.13 
Urinary pH (n=442) 0.3075 0.03415;0.5809 <0.05   0.2219 -0.0331;0.4769 0.0879 
Urinary 24 hr citrate (mmol/24h)
b
  (n=465) -0.2229 -0.4369;-0.0088 <0.05  -0.1359 -0.3287;0.0569 0.17 
Urinary 24 hr ammonium (mmol/24h)
c
  (n=83) -5.823 -23.88;12.23 0.52   2.083 -9.245;13.41 0.71 
Under low calcium and sodium diet 
       
Plasma bicarbonate (mmol/l)
a
  (n=281) 0.4404 -0.7242;1.605 0.46  0.5893 -0.5062;1.684 0.29 
Urinary pH  (n=346) 0.5047 0.2098;0.7996 <0.001   0.3805 0.1177;0.6433 <0.005 
Urinary 24 hr citrate (mmol/24h)
b
  (n=433) -0.0983 -0.3204;0.1239 0.39  -0.0665 -0.2783;0.1453 0.54 
Urinary 24 hr ammonium (mmol/24h)
c
  (n=64) -3.288 -25.89;19.31 0.77   8.240 -6.990;23.47 0.28 
The estimate E161K has the wildtype as reference group. For plasma bicarbonate, urinary pH and urinary 24 hr citrate the between-center variability was taken 
into account as a random effect for all models. Adjusted models were created by backward selection from a full additive model containing sex, age, BMI, 24 hr 
urinary sulfate excretion (as a marker for dietary acid intake) and net gastrointestinal alkali absorption (as a marker for dietary alkali intake), including non-linear 
terms and interactions where appropriate, as described in the statistical part. 
a
variables available in the center Bern only   
b
square-root-transformation were applied   
c
variables available in the center Dallas only. 
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Table 5: Associations between the E161K polymorphism and kidney stones estimated by mixed effects logistic regression models. 
p.E161.K adjusted for 
 
unadjusted 
 
sex 
 
age 
 
BMI sex & age   sex & BMI   age & BMI 
 
Kidney stones  
OR 
95% CI 
p 
 
OR 
95% CI 
p 
 
OR 
95% CI 
p 
 
OR 
95% CI 
p 
OR 
95% CI 
p 
 
OR 
95% CI 
p 
 
OR 
95% CI 
p 
                     
Calcium oxalat 
(present) 
  
0.57 
0.15;3.74 
0.47   
0.62 
0.16;4.10 
0.54   
1.06 
0.22;21.69 
0.88   
1.32 
0.25;2.45 
0.79 
1.21 
0.23;22.46 
0.86   
1.34 
0.25;2.49 
0.78   
1.3 
0.24;2.45 
0.80 
Calcium phosphate 
(present)  
3.71 
1.45;10.69 
<0.01 
 
3.60 
1.37;10.57 
<0.05 
 
2.89 
1.10;8.45 
<0.05 
 
3.28 
1.23;9.69 
<0.05 
2.90 
1.08;8.66 
<0.05 
 
3.32 
1.21;10.04 
<0.05 
 
2.78 
1.03;8.28 
<0.05 
Uric acid 
(present) 
  <0.001 0.86   <0.001 0.87   <0.001 0.99   <0.001 0.96 <0.001 0.95   <0.001 0.31   <0.001 0.97 
The estimate of E161K has the wildtype as reference group. The between-center variability was taken into account as a random effect in all models. Complete data of 365-388 kidney stone formers was available for 
inclusion in the regression models. 
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Table 6. Characteristics of patients that underwent ammonium chloride loading according to E161K 
heterozygosity (N=69)  
Characteristic   Wild-type   Heterozygote   p 
Center Bern   37 77.1%   13 61.9%   
0.19 
Center Dallas   11 22.9%   8 38.1%   
Age (yr) 
 
48 41.84 (34.5-50.6) 
 
21 39.5 (25.4-44.8) 
 
0.17 
Male sex   33 68.8%   15 71.4%   0.82 
The number of stone formers is indicated for each characteristic stratified by the genotype. Categorical 
variables are further described by % and continuous variables by their median (25
th
-75
th
 percentile). 
Between group differences are determined by Mann–Whitney U or chi-square test where appropriate and 
the corresponding p-value is indicated. 
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Table 7. Blood and urine parameters of non-stone formers according to E161K heterozygosity on random outpatient diet. 
Characteristic   
Normal 
range 
  Unit   N   Wild-type   N   Heterozygote   p 
Plasma Na   132 - 142   mmol/l   98   138(137-139)   9   138(138-139)   0.57 
Plasma K   3.5 - 4.7   mmol/l   98   4.3(4.1-4.5)   9   4.2(4.1-4.4)   0.69 
Plasma Cl   97 - 108   mmol/l   98   106(105-108)   9   106(104-106)   0.50 
Plasma Ca total   2.10 - 2.55   mmol/l   98   2.4(2.3-2.4)   9   2.3(2.3-2.4)   0.89 
Plasma P   0.84 - 1.45   mmol/l   96   1.1(0.9-1.2)   9   1.1(1-1.3)   0.33 
Plasma Mg   0.75 - 1.00   mmol/l   87   0.9(0.8-0.9)   7   0.9(0.7-0.9)   0.24 
Plasma Creatinine   45 - 84   µmol/l   88   80(62-88)   8   80(77-88)   0.66 
eGFR CKD-EPI   >90   
ml/min per 
1.73 m2 
  86   96(80-104)   8   88(84-92)   0.43 
Plasma uric acid   202 - 416   µmol/l   79   298(238-354)   8   283(171-341)   0.40 
Plasma random 
glucose 
  3.33 - 5.55   mmol/l   83   5(4.6-5.3)   8   4.8(4.6-4.9)   0.15 
Plasma 
Bicarbonate 
  18.0 - 29.0   mmol/l   95   27(25-28)   9   24(24-28)   0.15 
Serum PTH   15 - 65   pg/ml   61   30(24-39)   2   17(15-20)    ─ 
Urinary volume    ─   ml   75   1715(1173-2558)   8   1700(1579-2356)   0.49 
Urine pH    ─    ─   75   6.1(5.8-6.4)   8   6.2(6-6.3)   0.44 
Urine Na   40 - 220   mmol/ 24 hr   75   131(90-188)   8   149(125-184)   0.50 
Urine K   25 - 125   mmol/ 24 hr   74   49(35-63)   8   48(47-54)   0.64 
Urine Cl   110 - 250   mmol/ 24 hr   71   130(80-176)   7   132(127-173)   0.38 
Urine Ca   2.50 - 7.50   mmol/ 24 hr   75   3.4(1.9-4.9)   8   3.7(2.6-4.4)   0.58 
Urine P   13.0 - 42.0   mmol/ 24 hr   74   26(17.8-33.1)   8   24.4(21.8-27.3)   0.90 
Urine Mg   2.50 - 8.50   mmol/ 24 hr   75   3.7(2.8-4.4)   8   3.6(3.2-4)   0.78 
Urine uric acid   < 5900   µmol/ 24 hr   68   3015(2353-3972)   4   2927(2183-3823)   0.92 
Urine creatinine   
6300 - 
19400 
  µmol/ 24hr   75   11378(9101-15265)   8   12264(8890-13199)   0.99 
Urine citrate   1.65 - 6.6   mmol/ 24 hr   72   3.2(2.29-4.28)   7   2.54(2.2-2.67)   0.20 
Urine citrate/K    ─   
(mmol/24hr)/ 
(mmol/24hr) 
  72   0.065(0.045-0.085)   7   0.047(0.036-0.064)   0.21 
Urine K-P    ─   mmol/ 24 hr   74   23(12-35)   8   22(18-31)   0.68 
Urine citrate/K-P    ─   
(mmol/24hr)/ 
(mmol/24hr) 
  72   0.118(0.06-0.198)   7   0.102(0.06-0.161)   0.69 
NGIA    ─   mmol/ 24 hr   71   18.9(7.4-36.4)   7   30.6(22.9-32.4)   0.22 
Urine SO4    ─   mmol/ 24 hr   68   17(13-24)   4   18(16-21)   0.71 
Urine oxalate   <500   µmol/ 24 hr   68   284(193-359)   4   299(282-306)   0.79 
The number of participants is indicated for each characteristic stratified by the genotype. Continuous variables are further described 
by their median (25
th
-75
th
 percentiles). Between group differences are determined by Mann–Whitney U test and the corresponding 
p-value is indicated. Abbreviations: PTH, parathormone; NGIA, net gastrointestinal alkali intake; p, p-value. 
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Table 8. Blood and urine parameters of non-stone formers according to E161K heterozygosity on low Ca and Na diet. 
Characteristic   
Normal 
range 
  Unit   N Wild-type   N Heterozygote   p 
Urinary volume    ─   ml   40 1985(1428-2590)   5 1900(1500-1925)   0.75 
Urine pH    ─    ─   39 6.2(5.7-6.4)   5 6.7(6.3-6.7)   0.048 
Urine Na   40 - 220   mmol/ 24 hr   39 120(94-174)   5 144(119-266)   0.15 
Urine K   25 - 125   mmol/ 24 hr   39 47(37-66)   5 71(42-104)   0.29 
Urine Cl   110 - 250   mmol/ 24 hr   31 111(95-165)   5 132(117-239)   0.30 
Urine Ca   2.50 - 7.50   mmol/ 24 hr   39 3.1(2.1-4.2)   5 4.2(3.5-4.9)   0.24 
Urine P   13.0 - 42.0   mmol/ 24 hr   39 24(18-28)   5 26(26-33)   0.29 
Urine Mg   2.50 - 8.50   mmol/ 24 hr   39 3.6(2.6-4.6)   5 3.7(3.3-4)   0.85 
Urine uric acid   < 5900   µmol/ 24 hr   33 3147(2594-3683)   5 3176(3052-3295)   0.61 
Urine creatinine   6300 - 
13400 
  µmol/ 24hr 
  39 12314(9233-14666)   5 9980(8847-17079)   0.97 
Urine citrate   1.65 - 6.6   mmol/ 24 hr   35 3(2.1-4.9)   5 3(2.7-3.4)   0.84 
Urine citrate/K    ─   (mmol/24hr)/ 
(mmol/24hr)   34 0.067(0.05-0.091)   5 0.048(0.021-0.071)   0.24 
Urine K-P    ─   mmol/ 24 hr   39 26(18-37)   5 38(16-86)   0.52 
Urine citrate/K-P    ─   (mmol/24hr)/ 
(mmol/24hr)   34 0.123(0.081-0.2)   5 0.025(0.012-0.09)   0.035 
NGIA    ─   mmol/ 24 hr   30 14(-4-31)   5 45(8-91)   0.15 
Urine SO4    ─   mmol/ 24 hr   33 19(15-24)   5 21(18-23)   0.83 
Urine oxalate   <500   µmol/ 24 hr   33 289(228-411)   5 304(200-322)   0.60 
 
The number of stone formers is indicated for each characteristic stratified by the genotype. Continuous variables are further described 
by their median (25
th
-75
th
 percentiles). Between group differences are determined by Mann–Whitney U test and the corresponding p-
value is indicated. Abbreviations: NGIA, net gastrointestinal alkali intake; SO4, sulfate; p, p-value. 
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